InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INM InMed Pharmaceuticals Inc

Trading 01-10 12:02:28 EST

4.53

-0.25

-5.23%

High4.66	Low4.45	Vol19.33K
Open4.59	D1 Closing4.78	Amplitude4.39%
Mkt Cap3.25M	Tradable Cap3.23M	Total Shares718.03K
T/O87.83K	T/O Rate2.71%	Tradable Shares714.00K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"INM","market":"US","secType":"STK","nameCN":"InMed Pharmaceuticals Inc","latestPrice":4.53,"timestamp":1736528466259,"preClose":4.78,"halted":0,"volume":19328,"delay":0,"floatShares":714000,"shares":718032,"eps":-20.14294,"marketStatus":"Trading","change":-0.25,"latestTime":"01-10 12:02:28 EST","open":4.59,"high":4.66,"low":4.45,"amount":87825.79417600001,"amplitude":0.043933,"askPrice":4.53,"askSize":75,"bidPrice":4.26,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-20.14294,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1736542800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.78,"postHourTrading":{"tag":"盘后","latestPrice":4.78,"preClose":4.51,"latestTime":"16:00 EST","volume":29,"amount":138.62,"timestamp":1736370001873},"volumeRatio":1.278479},"requestUrl":"/m/hq/s/INM","defaultTab":"news","newsList":[{"id":"2493145167","title":"InMed Pharmaceuticals files to sell 3M common shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2493145167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493145167?lang=en_us&edition=fundamental","pubTime":"2024-12-24 06:25","pubTimestamp":1734992726,"startTime":"0","endTime":"0","summary":"17:21 EST InMed Pharmaceuticals (INM) files to sell 3M common shares for holders Published first on TheFly – the ultimate source for real-time, mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inmed-pharmaceuticals-files-to-sell-3m-common-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inmed-pharmaceuticals-files-to-sell-3m-common-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BK4534","MMM","BK4206","BK4007","BK4533","LU0787776722.HKD","BK4588","BK4512","LU0683600562.USD","BK4585","LU1093756325.SGD","INM"],"gpt_icon":0},{"id":"2493719049","title":"BRIEF-InMed Pharmaceuticals Files For Offering Of 3 Million Common Shares By Selling Stockholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2493719049","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493719049?lang=en_us&edition=fundamental","pubTime":"2024-12-24 06:18","pubTimestamp":1734992336,"startTime":"0","endTime":"0","summary":"BRIEF-InMed Pharmaceuticals Files For Offering Of 3 Million Common Shares By Selling StockholderDec 23  - InMed Pharmaceuticals Inc INM.O:INMED PHARMACEUTICALS INC FILES FOR OFFERING OF 3 MILLION COMMON SHARES BY SELLING STOCKHOLDER - SEC FILINGFurther company coverage: INM.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0AW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2493719077","title":"InMed Pharmaceuticals Inc Files for Offering of 3 Mln Common Shares by Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2493719077","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493719077?lang=en_us&edition=fundamental","pubTime":"2024-12-24 06:18","pubTimestamp":1734992288,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0AW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2492198274","title":"InMed Pharmaceuticals’ 2024 AGM Results Announced","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492198274?lang=en_us&edition=fundamental","pubTime":"2024-12-19 09:35","pubTimestamp":1734572103,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals announced the results of their 2024 Annual General Meeting, where shareho...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-2024-agm-results-announced?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-2024-agm-results-announced?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","BK4007","INM","AGM","BK4229"],"gpt_icon":0},{"id":"2492167633","title":"InMed Announces Results of 2024 Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2492167633","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492167633?lang=en_us&edition=fundamental","pubTime":"2024-12-19 09:00","pubTimestamp":1734570000,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia-- - InMed Pharmaceuticals Inc.  , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholders held on December 18, 2024 , the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 28, 2024, were voted upon by the shareholders. A total of 5,318,677 common shares of the Company, representing approximately 39.83% of the Company's 13,353,431 issued and outstanding common shares, were represented in person or by proxy at the Meeting.Results of the vote for the election of the board of directors  at the Meeting are set out as follows:","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/10T8HQgbALb6vC1wN3yrVg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/c4e1c36e02fcc1de98d748b5513c24b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/10T8HQgbALb6vC1wN3yrVg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/c4e1c36e02fcc1de98d748b5513c24b9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-announces-results-2024-annual-010000531.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmed-announces-results-2024-annual-010000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2492911215","title":"InMed Pharmaceuticals Secures $10 Million Equity Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492911215","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492911215?lang=en_us&edition=fundamental","pubTime":"2024-12-18 06:38","pubTimestamp":1734475133,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has entered into a Standby Equity Purchase Agreement with Yorkville Advis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-secures-10-million-equity-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-secures-10-million-equity-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","INM","BK4588","BK4585","EQR","BK4007"],"gpt_icon":0},{"id":"2492916910","title":"InMed Enters Into Standby Equity Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492916910","media":"Newsfile","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492916910?lang=en_us&edition=fundamental","pubTime":"2024-12-18 05:56","pubTimestamp":1734472560,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia-- - InMed Pharmaceuticals Inc.  , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase Agreement  with YA II PN, LTD , an investment fund managed by Yorkville Advisors Global LP, a global investment manager, on December 13, 2024  to sell up to $10 million in the aggregate of the Company's common shares, no value , at any time during the 36-month period following the Effective Date of the SEPA, subject to the effectiveness of a registration statement with the Securities and Exchange Commission and other conditions set forth in the SEPA.\"This equity facility is a key component of our financing strategy, offering both flexibility and extended runway to accelerate our pharmaceutical programs and other business development initiatives,\" said Eric A. Adams, Chief Executive Officer of InMed. \"This approach allows the Com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IiR1OjwcbQrR6_cW.IrFmg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/ef2de5a261d6a3352b332e15c245309d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IiR1OjwcbQrR6_cW.IrFmg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/ef2de5a261d6a3352b332e15c245309d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-enters-standby-equity-purchase-215600475.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmed-enters-standby-equity-purchase-215600475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4215","BK4588","BK4007","BK4585","INM","EQR"],"gpt_icon":0},{"id":"2484941575","title":"InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System","url":"https://stock-news.laohu8.com/highlight/detail?id=2484941575","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484941575?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:30","pubTimestamp":1732019400,"startTime":"0","endTime":"0","summary":"Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects. Supports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritus. Anti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application. The study, conducted in collaboration with Dr. Mauro Maccarrone at Università degli Studi dell'Aquila, investigated how CBN modulates the major elements of the endocannabinoid system  and activated receptors known to be involved in the inflammatory pathways of the skin. CBN was found to:. modulate the enzymes that regulate both AEA and 2-AG ;\"Our drug development programs have been focused on the role of inflammation in various diseases, such as Alzheimer's disease, age-related macular degeneration and epidermolysis bullosa and how rare cannabinoids and their analogs may be able to modulate the inflammation process,\" commented InMed's Senior VP, Preclinical Research a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0x_RfEseIPpvXbjggGOMEA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/fdf65ae51c996dad361e68738ab19e95","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0x_RfEseIPpvXbjggGOMEA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/fdf65ae51c996dad361e68738ab19e95"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-announces-publication-study-anti-123000871.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmed-announces-publication-study-anti-123000871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","INM"],"gpt_icon":1},{"id":"2483756043","title":"InMed Pharmaceuticals Yesterday Reported Q4 EPS $(2.17) Down From $(0.19) YoY, Sales $1.26M Up From $901.86K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483756043","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483756043?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:26","pubTimestamp":1731677195,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Yesterday Reported Q4 EPS $(2.17) Down From $(0.19) YoY, Sales $1.26M Up From $901.86K YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42007607/inmed-pharmaceuticals-yesterday-reported-q4-eps-2-17-down-from-0-19-yoy-sales-1-26m-up-from-901-86k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"InMed Pharmaceuticals Yesterday Reported Q4 EPS $(2.17) Down From $(0.19) YoY, Sales $1.26M Up From $901.86K YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM"],"gpt_icon":0},{"id":"2483845326","title":"InMed Pharmaceuticals Inc: Qtrly Loss per Share $2.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2483845326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483845326?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:05","pubTimestamp":1731668740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nFWN3MM0JO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2483316352","title":"InMed Pharmaceuticals Makes Progress on Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2483316352","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483316352?lang=en_us&edition=fundamental","pubTime":"2024-11-15 07:08","pubTimestamp":1731625701,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has made significant strides in its pharmaceutical programs, particularly...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-makes-progress-on-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-makes-progress-on-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PRGS","BK4097","INM","LU2065732104.USD"],"gpt_icon":0},{"id":"2483353548","title":"InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483353548","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483353548?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:45","pubTimestamp":1731620700,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia-- - InMed Pharmaceuticals Inc.  , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the first quarter of the fiscal year 2025 which ended September 30, 2024.Eric A. Adams, InMed Chief Executive Officer, commented, \"Fiscal 2025 has commenced on a positive trajectory, with notable progress across our pharmaceutical programs and commercial operations. Our Alzheimer's treatment candidate, INM-901, demonstrated robust progress in the first quarter, with initial read-out from a long-term preclinical study providing strong data, including achieving statistical significance in certain behavioural criteria. We are encouraged by the promising data supporting this program and the multiple potential mechanisms of action observed with this drug candidate. The Alzheimer's research landscape is rapidly evolving, with increasing attention on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-reports-first-quarter-fiscal-214500489.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmed-reports-first-quarter-fiscal-214500489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2098885051.SGD","LU1316542783.SGD","BK4575","BK4141","BK4585","LU0081259029.USD","BK4588","LU0823421416.USD","IE0009356076.USD","LU1064131342.USD","LU1303367103.USD","LU0823434740.USD","INM","GFS","BK4566","LU0642271901.SGD","LU0979878070.USD","LU2458330169.SGD","AMD","LU0127658192.USD","LU1880398554.USD","LU2054465674.USD","LU2458330243.SGD","LU1242518857.USD","LU0198837287.USD","LU1951198990.SGD","LU0823434583.USD","BK4573","LU2250418816.HKD","LU1988902786.USD","LU2360106780.USD","LU1880398471.USD","IE00BMPRXN33.USD","LU1803068979.SGD","LU0109392836.USD","LU1242518931.SGD","LU0082616367.USD","LU0719512351.SGD","IE00B5949003.HKD","LU0823421333.USD","BK4554","BK4512","BK4529","LU1951200564.SGD","LU0889565833.HKD","IE00BMPRXR70.SGD","LU1989764664.SGD","IE0004445239.USD","BK4532"],"gpt_icon":1},{"id":"2483135867","title":"InMed Pharmaceuticals Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2483135867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483135867?lang=en_us&edition=fundamental","pubTime":"2024-11-14 08:50","pubTimestamp":1731545407,"startTime":"0","endTime":"0","summary":"19:50 EST InMed Pharmaceuticals (INM) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inmed-pharmaceuticals-inc-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inmed-pharmaceuticals-inc-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2482454017","title":"InMed announces share consolidation to satisfy Nasdaq listing rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2482454017","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482454017?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:57","pubTimestamp":1731103044,"startTime":"0","endTime":"0","summary":"ipopba/iStock via Getty Images  InMed Pharmaceuticals  announced on Friday, that it will be consolidating all of its issued and outstanding share capital because of one 1 postconsolidation share for each twenty 20 preconsolidation common shares to regain compliance with all of Nasdaq's","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468430468/image_1468430468.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468430468/image_1468430468.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4268545-inmed-announces-share-consolidation-to-satisfy-nasdaq-listing-rules","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2482451886","title":"InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2482451886","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482451886?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:44","pubTimestamp":1731102240,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia-- - InMed Pharmaceuticals Inc.  , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced, pursuant to a directors' resolution, InMed will be consolidating all of its issued and outstanding share capital on the basis of one  postconsolidation share for each twenty  preconsolidation common shares, no par value, of the Company  in order to regain compliance with all of Nasdaq's continued listing requirements .Registered shareholders holding physical share certificates will receive by mail a letter of transmittal advising of the Consolidation and containing instructions. Holders of Common Shares who hold uncertificated Common Shares , either as registered holders or beneficial owners, will have their existing book-entry account electronically adjusted by the Company's transfer agent or, for beneficial shareholders, by their brokerage firms, banks, trusts ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dVao9n6DC.FqNxJGkSA9SQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/e786559924b07e811236a04d94b6b60b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dVao9n6DC.FqNxJGkSA9SQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/e786559924b07e811236a04d94b6b60b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-announces-share-consolidation-satisfy-214400669.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmed-announces-share-consolidation-satisfy-214400669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","BK4588","BK4585","BK4112","IE00BKPKM429.USD","INM",".IXIC","BK4007","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2481507970","title":"InMed Pharmaceuticals to Consolidate Shares for Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507970?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:11","pubTimestamp":1730815904,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has been granted a temporary exception by Nasdaq to implement a share con...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-to-consolidate-shares-for-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-to-consolidate-shares-for-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","INM","NQmain","IE00BKPKM429.USD","TQQQ","QID",".IXIC","NDAQ","BK4007","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4585","PSQ","LU2210149790.SGD","BK4112","SQQQ","MNQmain","QLD","BK4588","LU2095319765.USD"],"gpt_icon":0},{"id":"2481501958","title":"InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2481501958","media":"Newsfile","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481501958?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813400,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia-- - InMed Pharmaceuticals Inc.  , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the decision by the Nasdaq Listing Qualifications Panel  to grant an exception until December 2, 2024, to implement a share consolidation to satisfy the Nasdaq Listing Rules.Once deemed effective, the Consolidation will result in the number of issued and outstanding Common Shares being reduced from 14,361,550 to approximately 718,078 Common Shares on a non-diluted basis, and each of the Company's shareholders will hold the same overall percentage of Common Shares outstanding immediately after the Consolidation as such shareholder held immediately prior to the Consolidation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lZjG2WvYUSe44w8CrJXwdg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/bea8f78d78f6bd9f6b4112a0dd60eff2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lZjG2WvYUSe44w8CrJXwdg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/bea8f78d78f6bd9f6b4112a0dd60eff2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-pharmaceuticals-announces-decision-nasdaq-133000220.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmed-pharmaceuticals-announces-decision-nasdaq-133000220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","INM","PSQ","QID","BK4007","MNQmain","BK4585","NQmain","QLD","TQQQ","BK4588","LU2210149790.SGD","BK4112",".IXIC","SQQQ","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2478056100","title":"InMed Pharmaceuticals’ New Alzheimer’s Treatment Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2478056100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478056100?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:40","pubTimestamp":1730119238,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has filed an international patent application for INM-901, a small molecu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-new-alzheimers-treatment-patent?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-new-alzheimers-treatment-patent?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2478109711","title":"InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2478109711","media":"Newsfile","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478109711?lang=en_us&edition=fundamental","pubTime":"2024-10-28 19:30","pubTimestamp":1730115000,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia-- - InMed Pharmaceuticals Inc.  , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has filed an additional international patent application, under the Patent Cooperation Treaty , focused on the pharmaceutical composition and method of use for the proprietary small molecule drug candidate INM-901 for treating neurodegenerative diseases, including Alzheimer's disease.This PCT patent application encompasses several key components, including:. treatment of neuronal disorders, particularly those associated with neurodegeneration;potential to inhibit or slow the progression of neurodegenerative diseases by reducing cytotoxicity in affected neuron populations; and. use in promoting neurite elongation and/or restoring neurite formation in damaged neurons.can be administered orally and achieve therapeutic levels in the brain","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lT.qp10qlVfco1Apt3embA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/98b1f8becee2e147596642b6cef162b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lT.qp10qlVfco1Apt3embA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/98b1f8becee2e147596642b6cef162b8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-pharmaceuticals-files-additional-patent-113000710.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmed-pharmaceuticals-files-additional-patent-113000710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4090","PCT","INM"],"gpt_icon":1},{"id":"2478775698","title":"InMed Pharmaceuticals Showcases INM-901 at Biotech Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2478775698","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478775698?lang=en_us&edition=fundamental","pubTime":"2024-10-25 04:18","pubTimestamp":1729801126,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) has shared an announcement. InMed Pharmaceuticals is set to participate in the Fierce Biotech webinar on Alzheimer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-showcases-inm-901-at-biotech-webinar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-showcases-inm-901-at-biotech-webinar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inmedpharma.com","stockEarnings":[{"period":"1week","weight":-0.0485},{"period":"1month","weight":-0.1113},{"period":"3month","weight":0.0738},{"period":"6month","weight":-0.1491},{"period":"1year","weight":-0.4218},{"period":"ytd","weight":-0.0485}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.013838},{"month":2,"riseRate":0.5,"avgChangeRate":-0.085756},{"month":3,"riseRate":0.25,"avgChangeRate":-0.132085},{"month":4,"riseRate":0.5,"avgChangeRate":-0.018921},{"month":5,"riseRate":0.5,"avgChangeRate":-0.028557},{"month":6,"riseRate":0.25,"avgChangeRate":-0.179927},{"month":7,"riseRate":0.25,"avgChangeRate":-0.105641},{"month":8,"riseRate":0.25,"avgChangeRate":0.038545},{"month":9,"riseRate":0.25,"avgChangeRate":-0.144917},{"month":10,"riseRate":0.25,"avgChangeRate":-0.213206},{"month":11,"riseRate":0.25,"avgChangeRate":-0.042271},{"month":12,"riseRate":0.2,"avgChangeRate":-0.117815}],"exchange":"NASDAQ","name":"InMed Pharmaceuticals Inc","nameEN":"InMed Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"InMed Pharmaceuticals Inc,INM,InMed Pharmaceuticals Inc股票,InMed Pharmaceuticals Inc股票老虎,InMed Pharmaceuticals Inc股票老虎国际,InMed Pharmaceuticals Inc行情,InMed Pharmaceuticals Inc股票行情,InMed Pharmaceuticals Inc股价,InMed Pharmaceuticals Inc股市,InMed Pharmaceuticals Inc股票价格,InMed Pharmaceuticals Inc股票交易,InMed Pharmaceuticals Inc股票购买,InMed Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}